Dr. Judith Allen is a professor of Immunobiology at the University of Manchester. The Allen laboratory investigates the host immune response to parasite infection with a focus on type 2 immunity, the response mammals characteristically make to large multicellular parasites (helminths). Judi is particularly interested in the evolutionary relationship between type 2 immunity, parasite control and tissue repair and is currently investigating how the type 2 cytokines, IL-4 and IL-13, regulate the extra-cellular matrix. Dr. Allen’s research interests include understanding the opposing challenges faced by the immune system in response to micro vs macroparasites and is studying the relationship between type 2 cytokines and IL-17. Dr. Allen has been elected a Fellow of the Royal Society (2023), a Fellow of the Royal Society of Edinburgh, a Fellow of the Academy of Medical Sciences and is an EMBO member.
Nobel Laureate Dr. Drew Weissman is a professor of Medicine at the Perelman School of Medicine, University of Pennsylvania. Dr. Weissman, in collaboration with Nobel Laureate Dr. Katalin Karikó, discovered the ability of modified nucleosides in RNA to suppress activation of innate immune sensors and increase the translation of mRNA containing certain modified nucleosides. The nucleoside-modified mRNA-lipid nanoparticle vaccine platform Dr. Weissman’s lab created is used in the first 2 approved COVID-19 vaccines by Pfizer/BioNTech and Moderna. They continue to develop other vaccines that induce potent antibody and T cell responses with mRNA–based vaccines. Dr. Weissman’s lab also develops methods to replace genetically deficient proteins, edit the genome, and specifically target cells and organs with mRNA-LNPs, including lung, heart, brain, CD4+ cells, all T cells, and bone marrow stem cells.
For the full list of invited speakers in Cytokines 2024 & KAI 2024, please visit the official website.
Important Dates:
- Abstract Submission/ Travel Award Application by May 20, 2024
- Notifications of Abstract Acceptance by June 28, 2024
- Early-Registration by July 31, 2024
- Regular Registration by October 07, 2024